Kinetic Concepts, Inc. (NYSE: KCI) today announced the initial European and Canadian launch of the Prevena™ Incision Management System, the first and only powered negative pressure product designed specifically for management of surgically closed incisions. Studies have shown that the Prevena™ System may reduce the risk of post-operative complications, such as infection.
The Prevena™ Incision Management System is now available for use in hospitals throughout Europe and Canada. KCI estimates greater than three million procedures are performed each year worldwide that could benefit from treatment with the Prevena™ System, representing a potential global opportunity greater than $1 billion.
“The Prevena™ Incision Management System is an important part of KCI’s broader Negative Pressure Therapy Platform”
The Prevena™ Incision Management System is designed to create an environment that helps to promote healing by:
- Removing exudate and potentially infectious material
- Helping to hold the edges of the incision together
- Stimulating perfusion
- Reducing edema
- Protecting the surgical site from external infectious sources
“The Prevena™ Incision Management System is an important part of KCI’s broader Negative Pressure Therapy Platform,” said Mike Genau, KCI global president, Active Healing SolutionsTM. “Prevena™ represents a revolutionary solution for surgical incisions at risk for post-operative complications. Prevena™ further diversifies our Active Healing Solutions™ portfolio, and we are excited to offer a product that may play a role in preventing and minimizing surgical complications.”
Designed to conform to patient contours and help hold incision edges together, the Prevena™ Incision Management System includes a single dressing, worn for the duration of therapy, which acts as a barrier to external infectious sources. The Prevena™ System is indicated in the European Union and Canada for use over clean, closed incisions to manage the post-surgical environment and may reduce the likelihood of post-operative complications, such as surgical-site infection, dehiscence, hematoma and seroma. The system is intended for sale and single-patient use.
Dr. Nanne Kort, an orthopedic surgeon at Orbis Medical Park, the Netherlands, recently used the product for a patient and commented, “The incision was clean and closed, exactly what I was hoping for in this co-morbid patient. When standard of care is applied, I typically see moisture at the incision area, which increases opportunity for infection. At-risk patients ambulating in a non-clinical setting are also key patients for Prevena™ Therapy as multiple dressing changes could lead to increased secondary infection. And finally, Prevena™ Therapy may potentially enable patients to be discharged earlier in comparison to standard of care, which may decrease their overall cost of treatment, an area I am interested in studying.”